The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

BACKGROUND: Second-line treatment for advanced non-small-cell lung cancer (NSCLC) patients includes monotherapy with a third-generation cytotoxic drug (CT) or a tyrosine kinase inhibitor (TKI). These options are the actual standard for EGFR wild-type (WT) status, as patients with EGFR mutations achi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronte, Giuseppe, Franchina, Tindara, Alù, Massimiliano, Sortino, Giovanni, Celesia, Claudia, Passiglia, Francesco, Savio, Giuseppina, Laudani, Agata, Russo, Alessandro, Picone, Antonio, Rizzo, Sergio, De Tursi, Michele, Gambale, Elisabetta, Bazan, Viviana, Natoli, Clara, Blasi, Livio, Adamo, Vincenzo, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094963/
https://www.ncbi.nlm.nih.gov/pubmed/26993607
http://dx.doi.org/10.18632/oncotarget.8130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094963/
https://www.ncbi.nlm.nih.gov/pubmed/26993607
http://dx.doi.org/10.18632/oncotarget.8130

Ejemplares similares